Differentiation between field and vaccine strain of bluetongue virus serotype 16
Introduction
Bluetongue (BT) is an infectious, non-contagious disease caused by an arthropod-borne virus of the Orbivirus genus in the Reoviridae family; besides the Bluetongue virus (BTV), this genus includes other 20 serogroups as recently recognised by the International Committee for the Taxonomy of Viruses (Mertens et al., 2004). Within the BTV serogroup, 24 distinct serotypes have been identified by the virus-neutralisation test (VNT) and all of them used midges of the genus Culicoides as competent vectors (Mellor, 1992). The BTV genome consists of 10 double-stranded RNA segments distinguished from 1 to 10 on the basis of their molecular weight and electrophoretic mobility in 1% agarose gels. Each genome segment encodes for a viral protein for a total of seven structural (VP1–VP7) and four non-structural (NS1–NS3/A) proteins (Verwoerd et al., 1970, Roy et al., 1990a, Roy, 1992). The viral genome is surrounded by a double-layered protein capsid the outer part of which is composed by VP2 and VP5 (Roy, 1996). VP2, derived from segment 2, is the most variable protein (Roy, 1992), it is responsible for virus adsorption, entry into mammalian cells and might determine its virulence (Huismans et al., 1987). VP5, derived from segment 6, is not exposed on the virus surface. It serves as a scaffold for VP2 multimers (Huismans and Erasmus, 1981, Hassan and Roy, 1999) and though capable of binding to the cell surface, it cannot be internalised (Hassan et al., 2001). Both proteins are involved in the serotype specific antigenicity (Mertens et al., 1989). The NS1 protein is a non-structural protein encoded by segment 5. It has been found in BTV-infected cells to form tubular structures whose role is still to be determined (Hewat et al., 1992). The NS3/NS3A are also non-structural proteins differing for 13 amino acids only. Both proteins derived from segment 10, a very highly conserved gene among BTV strains and serotypes (Roy, 1996, Bonneau et al., 1999). The NS3/NS3A act as viral chaperones responsible for virus egression from either mammalian or insect cells (Bansal et al., 1998).
When infecting sheep, BTV might cause a severe clinical disease with mortality rates exceeding 10% (Mellor, 1994, Mellor, 1990, Koumbati et al., 1999). In cattle, goats and wild ruminants, the infection evolves mostly asymptomatically (Anderson et al., 1985). Due to its ability to spread rapidly under suitable circumstances, BT is classified by the Office International des Epizooties (OIE) as a notifiable disease (former List A). During outbreaks, affected countries are banned from trading in livestock and livestock products triggering serious socio-economic effects. Since 2000, Italy has experienced the most severe outbreaks of BT ever to be recorded involving at the beginning BTV serotypes 2 and 9, and then, from 2002, also 4 and 16. BTV has now been reported in Sardinia Sicily, Calabria, Basilicata, Puglia, Campania, Lazio, Tuscany, Abruzzo, Molise, Umbria, Emilia Romagna, Liguria and Marche (Anonymous, 2001, Anonymous, 2003). In an attempt to reduce direct losses due to disease and indirect losses due to virus circulation, since February 2002 the Italian government has been carrying out a compulsory BT vaccination campaign including all susceptible ruminants. Based on the serotype/s present in a given area, various monovalent serotype formulations of modified-live vaccine (MLV) produced by the Onderstepoort Biological Products (OBP), South Africa, were used. As a consequence of the new epidemiological scenario, in the first few months of the 2004 the monovalent BTV-16 modified-live vaccine either in combination with the monovalent BTV-2, BTV-4 and BTV-9 vaccines or with BTV-2 and BTV-4 was added in the composition and used in many Italian regions. Since May 2004, several BTV-16 seroconversions have been recorded in sentinel animals located either in vaccinated or unvaccinated areas supporting the hypothesis of vaccine strain circulation in the environment as already evidenced for BTV-2 (Ferrari et al., 2005). Although no scientific data were available for the BTV-16 vaccine strain, this event could not be discarded and a possible new scenario with both, vaccine and field BTV-16 isolates, contemporaneously circulating should be considered. In such a context, knowing exactly what kind of BTV-16 is circulating in a given area becomes crucial as such information will affect the livestock movement ban imposition with epidemiological and economical implications. This study compared the S2, 5, 6 and 10 sequences of the BTV-16 wild-type virus isolated in 2002 with those of the homologous vaccine strain, identified differences and developed a diagnostic method able to distinguish the two viruses.
Section snippets
Field and vaccine strains
The field strain of BTV-16 (94280/02) was an isolate recovered in 2002 from the blood of a cow belonging to a sentinel herd located in the community of Taviano in the province of Lecce, Puglia.
The BTV-16 vaccine strain used was the MLV (batch no. 2, 2003) manufactured by Onderstepoort Biological Products, Onderstepoort, South Africa and used during the 2004 Italian vaccination campaign.
Nucleic acid extraction
The total RNA was extracted from 250 μl of whole blood using TRIzol® reagent (Invitrogen, NZ) according to the
Segment 2
The open reading frame of both BTV-16 S2 gene segment was 2880 nucleotides in length sharing 99.9% homology. Similarly, the VP2 proteins consisting of 959 amino acids, were almost identical (99.6% of homology) differing only in leucine instead of a tryptophan in position 593.
Segment 6
The S6 nucleotide sequences of the BTV-16 included in the study contained 1637 bp with a single open reading frame encoding a predicted VP5 protein of 526 residues. As for the S2 gene segment, when the S6 sequences were
Discussion
Since 2000, Italy has been affected by the most severe and long-lasting bluetongue epidemic ever experienced in the Mediterranean basin. After the first outbreak reported in Sardinia, the infection extended to central and southern Italy involving initially BTV serotypes 2 and 9, and later, 4 and 16 (Calistri et al., 2004). Starting from January 2002, the Italian Ministry of Health implemented a vaccination campaign against BTV in affected and surrounding areas. According to a risk assessment
References (37)
- et al.
Sequence comparison of the L2 and S10 genes of bluetongue viruses from United States and the People's Republic of China
Virus Res.
(1999) - et al.
Neutralizing determinants of United States bluetongue virus serotype ten
Virology
(1993) Conserved and non-conserved regions of the outer coat protein VP2 of the Australian bluetongue serotype 1 virus revealed by sequence comparison to the VP2 of North American BTV serotype10
Virus Res.
(1988)- et al.
The complete nucleotide sequence of outer coat protein, VP5, of the Australian bluetongue virus (BTV) serotype 1 reveals conserved and non-conserved sequences
Virus Res.
(1988) - et al.
Relationship amongst bluetongue viruses revealed by comparisons of capsid and outer coat protein nucleotide sequences
Virus Res.
(1990) - et al.
3-D reconstruction of bluetongue virus tubules using cryoelectron microscopy
J. Struct. Biol.
(1992) - et al.
Duration of bluetongue viraemia and serological responses in experimentally infected European breeds of sheep and goats
Vet. Microbiol.
(1999) Epizootiology and vectors of African horse sickness virus
Comp. Immunol. Microbiol. Dis.
(1994)- et al.
Analysis of the roles of bluetongue virus outer capsid proteins VP2 and VP5 in determination of virus serotype
Virology
(1989) - et al.
Homotypic and heterotypic neutralization determinants of bluetongue virus serotype 17
Virology
(1995)
Phylogenetic analysis of the S10 gene of field and laboratory strains of bluetongue virus from the United States
Virus Res.
Subclinical and clinical disease in cattle: clinical, pathological and pathogenic considerations
Membrane organization of bluetongue virus non-structural glycoprotein NS3
J. Virol.
Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy
Prev. Vet. Med.
Cited by (50)
Bluetongue virus serotype 6 in Europe in 2008-Emergence and disappearance of an unexpected non-virulent BTV
2012, Veterinary MicrobiologyCitation Excerpt :In our study, BTV6/net08 was isolated from a naturally infected cow positive for nAbs for serotype 6 and 8. In general, the viremia of live-attenuated BT vaccines could vary in the recipient, e.g. BTV2 and 9 versus BTV16 (Monaco et al., 2006). An extreme low rate of transmission of BTV6/net08 has been suggested in both Germany and the Netherlands, but at present there is no conclusive explanation.
Evaluation of humoral response and protective efficacy of two inactivated vaccines against bluetongue virus after vaccination of goats
2011, VaccineCitation Excerpt :Since 2005, some inactivated BTV vaccines (directed against serotypes 2 and 4) have been used in Europe and have been shown to be safe and effective [13–15]. In the same period, the risks associated with the use of live vaccines were observed in the field: in Italy, the live attenuated BTV-2 vaccine spread to naïve populations by infectious vectors and the insufficient attenuation of the BTV-16 attenuated vaccine strain was observed [10,16]. After the introduction of BTV-8 in 2006, this serotype spread throughout Europe, causing severe disease and heavy financial losses in Western and Central Europe, especially in cattle.
Risk factors associated with the occurrence of undesired effects in sheep and goats after field vaccination with modified-live vaccine against bluetongue virus serotypes 2, 4 and 16
2010, Veterinary MicrobiologyCitation Excerpt :Problems related to the BTV-16 MLV have already been described. In 2004, after the BT Italian vaccination campaign which included BTV-16 MLV manufactured by OBP, many vaccinated and unvaccinated animals became ill because of BTV-16 vaccine strain infection (Monaco et al., 2006). The incidents were attributed to the inadequate attenuation of the vaccine strain employed and for this reason the use of BTV-16 monovalent MLV was discontinued a few months after the beginning of the campaign (Italian Ministry of Health, 2005).
First evidence of bluetongue virus serotype 16 in Croatia
2009, Veterinary MicrobiologyBluetongue
2021, Veterinary Vaccines: Principles and Applications